Today, Coloplast is announcing changes to the company’s Executive Leadership Team (ELT). The changes relate to the company’s Interventional Urology business as well as the global People & Culture function. Executive Vice President of People & Culture, Dorthe Rønnau, has decided to leave Coloplast to pursue the next chapter in her career. She has spent close to three decades in different roles across the Coloplast Group. “Dorthe’s values, integrity and strong leadership skills have benefitted the company acr ...

Notice of Annual General Meeting 2025 The Annual General Meeting of Coloplast A/S will be held on Thursday, 4 December 2025 at 3:30 pm CET at the premises of Coloplast A/S, Holtedam 3 in Humlebæk (the Aage Louis-Hansen Auditorium), Humlebæk, Denmark. The notice of the Annual General Meeting is enclosed. For further information, please contact Investors and analystsAnders Lonning-SkovgaardExecutive Vice President, CFOTel. +45 4911 1111 Kristine Husted MunkSr. Director, Investor RelationsTel. +45 4911 1800 ...

财务业绩摘要 - 2024/25财年有机增长达7%，息税前利润率为28% [1] - 报告收入以丹麦克朗计算增长3%至278.74亿丹麦克朗 [1] - 息税前利润为76.7亿丹麦克朗，较去年增长5% [8] - 调整后特殊项目前净利润为51.48亿丹麦克朗，较去年增加1.23亿丹麦克朗 [8] - 调整后特殊项目前稀释每股收益增长2%至22.84丹麦克朗 [8] 各业务板块有机增长 - 造口护理业务有机增长率为6% [1] - 失禁护理业务有机增长率为8% [1] - 嗓音与呼吸护理业务有机增长率为9% [1] - 伤口与组织修复业务有机增长率为8% [1] - 介入泌尿业务有机增长率为2% [1] 资本回报与现金流 - 调整后税后特殊项目前投入资本回报率为15%，与去年持平 [8] - 调整后自由现金流与销售额之比为19%，去年为15% [8] - 董事会建议年终股息为每股18.00丹麦克朗，全年总股息为每股23.00丹麦克朗，去年为每股22.00丹麦克朗 [2] 2025/26财年业绩指引 - 预计恒定汇率下有机收入增长约7%，息税前利润增长约7% [5] - 预计投入资本回报率约为16%，较去年调整后的15%提升约1个百分点 [6] - 以丹麦克朗计的报告增长预计为4%-5%，受汇率负面影响2-3个百分点 [5] - 资本性支出与销售额之比预计约为5%，实际税率预计约为22% [6] 可持续发展表现 - 2024/25财年生产废物回收率提升至83%，高于2025年75%的目标 [3] - 绝对范围1和范围2排放量较基准年2018/19年下降41%，去年为下降22% [4] - 损失工时工伤频率为1.7 ppm，较2023/24财年的2.1 ppm有所改善 [4] 特殊项目与战略投资 - 2024/25财年特殊项目费用为4.69亿丹麦克朗，涉及盈利能力提升举措、皮肤护理业务剥离、管理层重组及Atos Medical整合 [2] - 2025/26财年息税前利润增长预期包含与Impact4战略相关的新投资，以及Kerecis息税前利润率提升至约20% [6]